DE69419748T2 - GEN DES VON HIPPEL-LINDAU (VHL) SYNDROMS UND ENTSPRECHENDE cDNS UND METHODEN ZUR DETEKTION VON TRÄGERN DES ENTSPRECHENDEN GENS - Google Patents

GEN DES VON HIPPEL-LINDAU (VHL) SYNDROMS UND ENTSPRECHENDE cDNS UND METHODEN ZUR DETEKTION VON TRÄGERN DES ENTSPRECHENDEN GENS

Info

Publication number
DE69419748T2
DE69419748T2 DE69419748T DE69419748T DE69419748T2 DE 69419748 T2 DE69419748 T2 DE 69419748T2 DE 69419748 T DE69419748 T DE 69419748T DE 69419748 T DE69419748 T DE 69419748T DE 69419748 T2 DE69419748 T2 DE 69419748T2
Authority
DE
Germany
Prior art keywords
gene
vhl
lindau
methods
hippel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69419748T
Other languages
English (en)
Other versions
DE69419748D1 (de
Inventor
Michael I Lerman
Farida Latif
Berton Zbar
Marston Linehan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69419748D1 publication Critical patent/DE69419748D1/de
Application granted granted Critical
Publication of DE69419748T2 publication Critical patent/DE69419748T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
DE69419748T 1993-05-14 1994-05-12 GEN DES VON HIPPEL-LINDAU (VHL) SYNDROMS UND ENTSPRECHENDE cDNS UND METHODEN ZUR DETEKTION VON TRÄGERN DES ENTSPRECHENDEN GENS Expired - Lifetime DE69419748T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/061,889 US5654138A (en) 1993-05-14 1993-05-14 Von hippel-lindau (VHL) disease gene and corresponding cDNA and methods for detecting carriers of the VHL disease gene
PCT/US1994/005378 WO1994026894A1 (en) 1993-05-14 1994-05-12 VON HIPPEL-LINDAU (VHL) DISEASE GENE AND CORRESPONDING cDNA AND METHODS FOR DETECTING CARRIERS OF THE VHL DISEASE GENE

Publications (2)

Publication Number Publication Date
DE69419748D1 DE69419748D1 (de) 1999-09-02
DE69419748T2 true DE69419748T2 (de) 1999-12-09

Family

ID=22038796

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69419748T Expired - Lifetime DE69419748T2 (de) 1993-05-14 1994-05-12 GEN DES VON HIPPEL-LINDAU (VHL) SYNDROMS UND ENTSPRECHENDE cDNS UND METHODEN ZUR DETEKTION VON TRÄGERN DES ENTSPRECHENDEN GENS

Country Status (11)

Country Link
US (2) US5654138A (de)
EP (1) EP0698093B1 (de)
JP (1) JP3650397B2 (de)
AT (1) ATE182622T1 (de)
AU (1) AU696234B2 (de)
CA (1) CA2162928A1 (de)
DE (1) DE69419748T2 (de)
DK (1) DK0698093T3 (de)
ES (1) ES2135581T3 (de)
GR (1) GR3030876T3 (de)
WO (1) WO1994026894A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312890B1 (en) * 1993-05-14 2001-11-06 The United States Of America As Represented By The Department Of Health And Human Services Partial intron sequence of von hippel-lindau (VHL) disease gene and its use in diagnosis of disease
US6013436A (en) * 1994-07-08 2000-01-11 Visible Genetics, Inc. Compositions and methods for diagnosis of mutation in the von Hippel-Lindau tumor suppressor gene
AU7142796A (en) * 1995-10-02 1997-04-28 Erasmus University Rotterdam Diagnosis method and reagents
US5830657A (en) * 1996-05-01 1998-11-03 Visible Genetics Inc. Method for single-tube sequencing of nucleic acid polymers
US5789168A (en) * 1996-05-01 1998-08-04 Visible Genetics Inc. Method for amplification and sequencing of nucleic acid polymers
US5888736A (en) * 1995-12-22 1999-03-30 Visible Genetics, Inc. Method, compositions and kit for detection and identification of microorganisms
WO1997041259A1 (en) * 1996-05-01 1997-11-06 Visible Genetics Inc. Method for sequencing of nucleic acid polymers
US6083699A (en) * 1996-05-01 2000-07-04 Visible Genetics Inc. Method for bi-directional sequencing of nucleic acid polymers
US6214555B1 (en) 1996-05-01 2001-04-10 Visible Genetics Inc. Method compositions and kit for detection
US6413718B1 (en) 1996-05-01 2002-07-02 Visible Genetics Inc. Method for sequencing of nucleic acid polymers
US6977161B2 (en) * 2000-10-14 2005-12-20 Eragen Biosciences, Inc. Solid support assay systems and methods utilizing non-standard bases
ATE497018T1 (de) 2000-05-19 2011-02-15 Eragen Biosciences Inc Materialien und methoden zum nachweis von nukleinsäuren
US7222059B2 (en) 2001-11-15 2007-05-22 Siemens Medical Solutions Diagnostics Electrophoretic trace simulator
NZ520322A (en) * 2002-07-19 2005-04-29 Auckland Uniservices Ltd Tumor treating composition and methods
US20050208023A1 (en) * 2002-07-19 2005-09-22 Krissansen Geoffrey W Tumor treating composition and methods
AU2003296438A1 (en) * 2002-12-24 2004-07-29 North Carolina State University Increasing gamete production with a gene switch
US7494467B2 (en) * 2004-04-16 2009-02-24 Ethicon Endo-Surgery, Inc. Medical system having multiple ultrasound transducers or an ultrasound transducer and an RF electrode
US9261498B2 (en) * 2005-03-17 2016-02-16 The Regents Of The University Of California Biomarker for sensitivity to mTOR inhibitor therapy in kidney cancer
WO2012166824A2 (en) * 2011-05-31 2012-12-06 Oregon Health And Science University Methods and kits that identify tumors responsive to src inhibitors
EP2747552A1 (de) * 2011-08-23 2014-07-02 University of South Florida Induzierbare mausmodelle von lungenläsionen und lungenerkrankungen
CN110066874A (zh) * 2019-04-26 2019-07-30 复旦大学附属华山医院 血管母细胞瘤分型诊断试剂盒

Also Published As

Publication number Publication date
CA2162928A1 (en) 1994-11-24
US5759790A (en) 1998-06-02
WO1994026894A1 (en) 1994-11-24
DE69419748D1 (de) 1999-09-02
DK0698093T3 (da) 1999-11-29
ATE182622T1 (de) 1999-08-15
JPH08511158A (ja) 1996-11-26
AU6833794A (en) 1994-12-12
US5654138A (en) 1997-08-05
EP0698093B1 (de) 1999-07-28
JP3650397B2 (ja) 2005-05-18
EP0698093A1 (de) 1996-02-28
AU696234B2 (en) 1998-09-03
GR3030876T3 (en) 1999-11-30
ES2135581T3 (es) 1999-11-01

Similar Documents

Publication Publication Date Title
ATE182622T1 (de) Gen des von hippel-lindau (vhl) syndroms und entsprechende cdns und methoden zur detektion von trägern des entsprechenden gens
DE69738670D1 (de) Verfahren zur oligomerisation von peptiden
DE3787713D1 (de) System zur Verarbeitung verschlüsselt übertragener Informationen.
DE3785788D1 (de) Vorrichtung zur bewertung der guete von reiskoernern.
DE69636147D1 (de) Verfahren zur herstellung von phosphorothioat-oligomeren
ATE269974T1 (de) Identifizierung und charakterisierung von interagierenden molekülen mittels automatisierter interagierender paarung
ES8702431A1 (es) Procedimiento para preparar una proteina inhibidora de la coagulacion de la sangre
DE3789053T2 (de) Vorrichtung zur Behandlung von Hypertrophie der Vorsteherdrüse.
DE3884653D1 (de) Verfahren und Vorrichtung zur Gasphasenabscheidung von Diamant.
NO974946L (no) Universale mål for artsidentifisering
BG101687A (en) Substituted azetidin-2-ones for treatment of atherosclerosis
DE69636453D1 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
DK0486515T3 (da) Fremgangsmåde til bestemmelse af den funktionelle aktivitet af frit protein S eller protein C i en plasmaprøve
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
DE3884612T2 (de) Interpolator zur expansion von videodaten.
ATE186575T1 (de) Verfahren zur identifizierung von menschlichen und tierischen zellen mit der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
ATE203766T1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
NO872936D0 (no) Fremgangsmaate for rensing av gasser avgitt fra aluminiumelektrolyseovner, og beslektet utstyr.
DE69638341D1 (de) Anzeigeprozessorsystem für eine punktorganisierte Anzeige von Wellenformdaten
DE3882259T2 (de) Apparat zur Behandlung von Verbrennungsabgas.
NO901614L (no) Luminescens-undersoekelse av enzymer.
DE3773106D1 (de) Methode zur entschwefelung von rauchgas.
DE3773875D1 (de) Methode zur hemmung der multiplikation des bacillus cereus.
HUP9901346A2 (hu) Deltap62 polipeptid és variánsai, ezeket kódoló nukleinsav-szekvenciák és felhasználásuk
DE68904322T2 (de) Einrichtung zur behandlung von gasen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition